A new scientific paper on BioBran/MGN-3 has been published by a research team led by Mai Alaa El-Dein, Doaa A. Ali, and Mamdooh H. Ghoneum. The paper is titled “Biobran/MGN-3, Arabinoxylan Rice Bran, Ameliorates the Liver Architecture in Ehrlich Ascites Tumor-Bearing Mice as a Cotreatment with Chemotherapy.”

In this preclinical study using an Ehrlich ascites carcinoma (EAC) mouse model, co-administration of BioBran/MGN-3 with paclitaxel reduced tumor volume and weight more effectively than either treatment alone. It was also associated with improved liver function markers (AST, ALT, and γGT), restoration of liver tissue architecture, and reduced collagen deposition, with microscopic findings suggestive of Kupffer cell activation.

These findings suggest that BioBran/MGN-3 may have potential as a supportive adjunct in cancer treatment, although further studies are needed to determine its clinical relevance in humans.

Journal: Integrative Cancer Therapies. 2026;25:1–13.
Authors: Mai Alaa El-Dein, Doaa A. Ali, Mamdooh H. Ghoneum
DOI: 10.1177/15347354261430853